Evolus Net Tangible Assets vs Non Current Liabilities Total Analysis

EOLS Stock

USD 13.59 0.11 0.80%

Evolus financial indicator trend analysis is much more than just examining Evolus Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evolus Inc is a good investment. Please check the relationship between Evolus Net Tangible Assets and its Non Current Liabilities Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Net Tangible Assets vs Non Current Liabilities Total

Net Tangible Assets vs Non Current Liabilities Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evolus Inc Net Tangible Assets account and Non Current Liabilities Total. At this time, the significance of the direction appears to have weak relationship.

The correlation between Evolus' Net Tangible Assets and Non Current Liabilities Total is 0.39. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Evolus Inc, assuming nothing else is changed. The correlation between historical values of Evolus' Net Tangible Assets and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Evolus Inc are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Net Tangible Assets i.e., Evolus' Net Tangible Assets and Non Current Liabilities Total go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Non Current Liabilities Total

Most indicators from Evolus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evolus Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Evolus' Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.91 in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

Evolus fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Good Will	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Non Currrent Assets Other	Capital Surpluse
Total Assets		0.46	0.69	0.14	-0.77	0.74	0.3	-0.36	-0.76	0.43	0.93	0.19	-0.27	0.73	0.61	0.88	0.59	0.22	0.77	-0.93	0.55	1.0	-0.25	-0.39	-0.92	0.85
Short Long Term Debt Total	0.46		0.42	0.83	-0.3	0.0	-0.6	0.64	-0.38	0.12	0.16	0.1	-0.25	0.34	0.25	0.27	0.06	0.17	0.85	-0.56	0.86	0.45	0.62	-0.22	-0.59	0.48
Other Current Liab	0.69	0.42		0.39	-0.81	0.51	-0.14	-0.23	-0.63	0.18	0.72	0.13	-0.2	0.51	0.32	0.63	0.69	0.05	0.77	-0.57	0.21	0.69	-0.07	-0.28	-0.56	0.52
Total Current Liabilities	0.14	0.83	0.39		-0.31	-0.2	-0.85	0.67	-0.05	0.0	-0.07	0.1	0.06	0.0	-0.13	-0.14	-0.12	-0.18	0.67	-0.24	0.65	0.14	0.87	0.05	-0.27	0.1
Total Stockholder Equity	-0.77	-0.3	-0.81	-0.31		-0.55	-0.13	0.43	0.36	-0.09	-0.83	-0.4	-0.15	-0.34	-0.14	-0.52	-0.55	0.34	-0.61	0.59	-0.29	-0.77	0.01	-0.04	0.58	-0.44
Other Liab	0.74	0.0	0.51	-0.2	-0.55		0.46	-0.64	-0.51	0.28	0.84	0.12	-0.21	0.44	0.32	0.75	0.28	0.13	0.4	-0.75	0.21	0.74	-0.48	-0.19	-0.73	0.58
Net Tangible Assets	0.3	-0.6	-0.14	-0.85	-0.13	0.46		-0.82	-0.13	0.06	0.48	0.07	-0.01	0.22	0.29	0.39	0.32	0.04	-0.37	-0.15	-0.32	0.3	-0.82	-0.08	-0.11	0.22
Net Debt	-0.36	0.64	-0.23	0.67	0.43	-0.64	-0.82		0.19	-0.17	-0.65	-0.18	-0.16	-0.22	-0.14	-0.44	-0.44	0.13	0.21	0.18	0.45	-0.37	0.79	-0.01	0.15	-0.19
Retained Earnings	-0.76	-0.38	-0.63	-0.05	0.36	-0.51	-0.13	0.19		-0.64	-0.67	0.29	0.62	-0.94	-0.91	-0.86	-0.68	-0.75	-0.7	0.77	-0.37	-0.76	0.41	0.84	0.76	-0.9
Accounts Payable	0.43	0.12	0.18	0.0	-0.09	0.28	0.06	-0.17	-0.64		0.34	-0.04	-0.08	0.69	0.55	0.51	0.3	0.57	0.38	-0.5	0.17	0.44	-0.29	-0.48	-0.48	0.59
Cash	0.93	0.16	0.72	-0.07	-0.83	0.84	0.48	-0.65	-0.67	0.34		0.19	-0.18	0.63	0.5	0.84	0.65	0.09	0.58	-0.81	0.27	0.94	-0.45	-0.3	-0.79	0.72
Non Current Assets Total	0.19	0.1	0.13	0.1	-0.4	0.12	0.07	-0.18	0.29	-0.04	0.19		0.76	-0.12	-0.48	0.12	0.03	-0.61	0.1	-0.05	0.01	0.19	0.18	0.73	-0.05	-0.05
Good Will	-0.27	-0.25	-0.2	0.06	-0.15	-0.21	-0.01	-0.16	0.62	-0.08	-0.18	0.76		-0.4	-0.69	-0.38	-0.22	-0.76	-0.3	0.35	-0.25	-0.25	0.29	0.81	0.36	-0.4
Common Stock Shares Outstanding	0.73	0.34	0.51	0.0	-0.34	0.44	0.22	-0.22	-0.94	0.69	0.63	-0.12	-0.4		0.9	0.85	0.69	0.69	0.63	-0.75	0.37	0.75	-0.4	-0.76	-0.73	0.95
Short Term Investments	0.61	0.25	0.32	-0.13	-0.14	0.32	0.29	-0.14	-0.91	0.55	0.5	-0.48	-0.69	0.9		0.71	0.6	0.82	0.46	-0.64	0.35	0.61	-0.46	-0.93	-0.62	0.85
Non Current Liabilities Total	0.88	0.27	0.63	-0.14	-0.52	0.75	0.39	-0.44	-0.86	0.51	0.84	0.12	-0.38	0.85	0.71		0.67	0.49	0.64	-0.83	0.31	0.88	-0.53	-0.52	-0.81	0.88
Other Current Assets	0.59	0.06	0.69	-0.12	-0.55	0.28	0.32	-0.44	-0.68	0.3	0.65	0.03	-0.22	0.69	0.6	0.67		0.28	0.4	-0.38	-0.09	0.6	-0.49	-0.47	-0.36	0.58
Other Stockholder Equity	0.22	0.17	0.05	-0.18	0.34	0.13	0.04	0.13	-0.75	0.57	0.09	-0.61	-0.76	0.69	0.82	0.49	0.28		0.27	-0.36	0.17	0.22	-0.41	-0.88	-0.35	0.58
Total Liab	0.77	0.85	0.77	0.67	-0.61	0.4	-0.37	0.21	-0.7	0.38	0.58	0.1	-0.3	0.63	0.46	0.64	0.4	0.27		-0.81	0.74	0.77	0.26	-0.39	-0.82	0.74
Deferred Long Term Liab	-0.93	-0.56	-0.57	-0.24	0.59	-0.75	-0.15	0.18	0.77	-0.5	-0.81	-0.05	0.35	-0.75	-0.64	-0.83	-0.38	-0.36	-0.81		-0.72	-0.93	0.13	0.48	1.0	-0.9
Short Long Term Debt	0.55	0.86	0.21	0.65	-0.29	0.21	-0.32	0.45	-0.37	0.17	0.27	0.01	-0.25	0.37	0.35	0.31	-0.09	0.17	0.74	-0.72		0.55	0.51	-0.27	-0.75	0.59
Total Current Assets	1.0	0.45	0.69	0.14	-0.77	0.74	0.3	-0.37	-0.76	0.44	0.94	0.19	-0.25	0.75	0.61	0.88	0.6	0.22	0.77	-0.93	0.55		-0.25	-0.39	-0.92	0.86
Short Term Debt	-0.25	0.62	-0.07	0.87	0.01	-0.48	-0.82	0.79	0.41	-0.29	-0.45	0.18	0.29	-0.4	-0.46	-0.53	-0.49	-0.41	0.26	0.13	0.51	-0.25		0.37	0.09	-0.28
Intangible Assets	-0.39	-0.22	-0.28	0.05	-0.04	-0.19	-0.08	-0.01	0.84	-0.48	-0.3	0.73	0.81	-0.76	-0.93	-0.52	-0.47	-0.88	-0.39	0.48	-0.27	-0.39	0.37		0.47	-0.68
Non Currrent Assets Other	-0.92	-0.59	-0.56	-0.27	0.58	-0.73	-0.11	0.15	0.76	-0.48	-0.79	-0.05	0.36	-0.73	-0.62	-0.81	-0.36	-0.35	-0.82	1.0	-0.75	-0.92	0.09	0.47		-0.89
Capital Surpluse	0.85	0.48	0.52	0.1	-0.44	0.58	0.22	-0.19	-0.9	0.59	0.72	-0.05	-0.4	0.95	0.85	0.88	0.58	0.58	0.74	-0.9	0.59	0.86	-0.28	-0.68	-0.89

Click cells to compare fundamentals

Evolus Account Relationship Matchups

Evolus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	240.4M	209.1M	257.5M	178.0M	189.0M	190.3M
Short Long Term Debt Total	96.5M	138.3M	74.7M	73.2M	126.5M	103.1M
Other Current Liab	17.4M	72.9M	42.4M	2.4M	31.6M	21.2M
Total Current Liabilities	24.4M	180.2M	57.7M	46.5M	48.3M	61.0M
Total Stockholder Equity	(213.1M)	(376.1M)	(422.9M)	18.5M	(20.7M)	(21.7M)
Other Liab	59.1M	58.1M	44.5M	39.9M	45.9M	46.9M
Net Tangible Assets	(1.4M)	(149.5M)	10.0M	(51.3M)	(59.0M)	(62.0M)
Net Debt	(13.3M)	35.8M	(71.5M)	19.3M	63.7M	66.9M
Retained Earnings	(213.1M)	(376.1M)	(422.9M)	(497.3M)	(559.0M)	(531.0M)
Accounts Payable	5.8M	9.6M	6.1M	33.7M	4.3M	7.9M
Cash	109.9M	102.6M	146.3M	53.9M	62.8M	70.0M
Non Current Assets Total	88.2M	81.5M	78.7M	77.2M	76.6M	63.4M
Common Stock Shares Outstanding	28.2M	33.7M	49.8M	56.1M	56.9M	37.9M
Liabilities And Stockholders Equity	(52.1M)	(94.0M)	(247.3M)	178.0M	189.0M	198.4M
Non Current Liabilities Total	136.5M	101.8M	117.9M	113.0M	161.4M	94.2M
Other Current Assets	5.3M	7.0M	11.0M	5.6M	8.1M	5.2M
Total Liab	161.0M	282.0M	175.6M	159.5M	209.7M	178.1M
Total Current Assets	152.2M	127.6M	178.8M	100.8M	112.4M	103.1M
Intangible Assets	59.6M	55.3M	50.6M	48.6M	47.1M	43.2M
Non Currrent Assets Other	2.4M	240K	2.8M	2.8M	409.0K	388.5K
Other Assets	2.4M	3.7M	32.5M	2.8M	1.0	0.95
Net Invested Capital	170.9M	61M	153.1M	90.4M	99.7M	92.8M
Net Working Capital	127.8M	(52.6M)	121.1M	54.3M	64.1M	41.5M
Long Term Debt	91.5M	40.5M	71.2M	71.9M	120.4M	75.6M
Cash And Short Term Investments	129.8M	107.6M	146.3M	53.9M	62.8M	79.1M

Pair Trading with Evolus

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evolus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolus will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evolus Stock

0.79	VRDN	Viridian Therapeutics	Pair Corr
0.87	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr

Moving against Evolus Stock

0.5	STOK	Stoke Therapeutics	Pair Corr
0.46	DSGN	Design Therapeutics	Pair Corr

The ability to find closely correlated positions to Evolus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evolus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evolus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evolus Inc to buy it.

The correlation of Evolus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evolus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evolus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evolus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evolus Inc is a strong investment it is important to analyze Evolus' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Evolus' future performance. For an informed investment choice regarding Evolus Stock, refer to the following important reports:

How To Invest In Evolus

Details

Is Evolus Stock a good investment?

Details

What is Evolus' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Evolus Stock analysis

When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Transaction History View history of all your transactions and understand their impact on performance
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.04)

Revenue Per Share

3.821

Quarterly Revenue Growth

0.422

Return On Assets

(0.11)

Return On Equity

(4.73)

The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evolus Net Tangible Assets vs Non Current Liabilities Total Analysis

Net Tangible Assets vs Non Current Liabilities Total

Net Tangible Assets vs Non Current Liabilities Total Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Non Current Liabilities Total

Evolus fundamental ratios Correlations

Evolus Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evolus fundamental ratios Accounts

Pair Trading with Evolus

Moving together with Evolus Stock

Moving against Evolus Stock

Complementary Tools for Evolus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Currrent Assets Other	+ 1.0	Deferred Long Term Liab
Capital Surpluse	+ 0.95	Common Stock Shares Outstanding
Total Current Assets	+ 0.94	Cash
Cash	+ 0.93	Total Assets
Short Term Investments	+ 0.9	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.94	Retained Earnings
Total Current Assets	- 0.93	Deferred Long Term Liab
Intangible Assets	- 0.93	Short Term Investments
Deferred Long Term Liab	- 0.93	Total Assets
Non Currrent Assets Other	- 0.92	Total Current Assets
Non Currrent Assets Other	- 0.92	Total Assets